Navigation Links
DNA detectives find genetic markers for lung cancers most likely to recur
Date:3/12/2008

Researchers at the Johns Hopkins Kimmel Cancer Center have uncovered clearly recognizable genetic alterations in tumors and tissue removed from patients with early-stage lung cancers that look like good predictors of which of these cancers are more likely to recur.

The discovery, they say, could change the approach to treating even the smallest lung cancers - the size of a pea - which are known to recur within five years in 30 to 40 percent of patients.

This is DNA forensics for cancer, says Malcolm Brock, M.D., associate professor of surgery at Johns Hopkins. While there may be no trace of cancer that we can spot after surgery with a microscope, the DNA evidence from these tumors may have been left at the scene, especially in lymph nodes.

The particular molecular flags the team identified are chemicals known as methyl groups that latch on to the DNA ladder structure of a gene. Methylation is a commonly known phenomenon in the formation and development of cancers because they serve as signals to cells to switch certain genes on or off. Disruption in these signals may create a cascade of abnormal proteins that lead to cancer or its recurrence.

In the study published in the March 13 issue of the New England Journal of Medicine, Brock and his team report how they combed through more than 700 surgical samples from 167 early stage, non-small cell lung cancer patients searching for specific methylation patterns linked to the disease.

Tumor and lymph node tissue from 51 patients whose cancers recurred within 40 months were compared with samples from the remaining 116 patients whose cancers did not recur.

The scientists tested all the samples for methylation on seven genes linked to the development of lung cancer. Four of them - p16, H-cadherin, APC and RASSF1A - showed the highest amounts of methylation in patients whose cancers recurred.

For many of the genes, the study revealed a twofold difference in methyl marks between recurrent cancers and those that did not return.

The DNA evidence we see for many of the recurring cases suggests it may be wise if our work is confirmed to reclassify such cancers as advanced disease instead of early stage, says Brock.

Brock and his colleagues also found that cancers returned even more swiftly than average for 11 patients who had higher than normal methylation in a deadly combination of two genes known as p16 and H-cadherin located in both tumor tissue and a lymph node distant from the original tumor area. Eight of the 11 patients with this methylation pattern had cancers that returned within a year. By 30 months, the remaining three patients cancer had also recurred.

The investigators did analyze the results to quantify the odds that a particular patients cancer would recur, noting a five to 25-fold increase in risk depending on the particular methylation pattern. They caution that while some of the gene markers lack statistical significance because of small sample size, odds predictions are valid for the two most promising genes - p16 and H-cadherin.

Kimmel Cancer Center medical oncologist James Herman, M.D. says if these results are confirmed, it may lead doctors to consider treating high-risk patients more aggressively with chemotherapy after surgery. He also believes that therapies which target these gene patterns by stripping off methyl groups hold promise as well. These marks of aggressive disease also are themselves targets for therapy.

Additional studies of the methyl markers are under way on lung cancer patients currently being treated at Johns Hopkins.

Cure rates for lung cancer are far lower than for other common cancers such as breast or prostate. Lung cancer is the deadliest cancer and second most common in the United States.


'/>"/>

Contact: Vanessa Wasta
wastava@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Many Parents Share Genetic Test Findings With Kids
2. Genetic predisposition increases childhood asthma risk
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Test Spots Genetic Damage Done by Smoking
5. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
6. Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
7. Genetics Hold Promise, Challenges for Cancer Care
8. Researchers genetically engineer micro-organisms into tiny factories
9. Study Questions Genetic Screening for Treatable Diseases
10. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
11. Genetic variation affects smoking cessation treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... Research ... treatment helps to reduce the frequency and level of relapse. , ... Healthy Identity and Purpose,” will explore the critical tasks of the recovery phase ...
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment and retention ... and scientific initiatives have all marked the last 12 months at Roswell Park ... of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined the many ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... H. Van Allen have signed a joint enrollment and degree completion agreement. ... toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students ...
(Date:2/5/2016)... Pass, OR (PRWEB) , ... February 05, 2016 , ... ... with modern technology, such water may be safer than regular municipal or well water. ... advocate and radio host Sharon Kleyne, could go a long way toward increasing public ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... announced the election of Patrick McDermott as Chairman of the National Board of Directors. ... Pat as Chairman of the Board,” stated Leslie A. Chambers , APDA President ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... ALBANY, New York , February 5, 2016 /PRNewswire/ ... A new Transparency Market Research report states that the ... bn in 2014 and is predicted to reach US$185.9 ... a CAGR of 6.50% from 2014 to 2020. The ... Market: (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by ...
(Date:2/5/2016)... England , February 5, 2016 ... --> Today, VoicePower Ltd - The Speech Recognition People, announced ... been deployed to improve patient care, reduce turnaround times and to ... Wirral CCG ,- VoicePower client since 2013 Challenge: ... Challenge: --> - Six doctors ,- Wirral CCG ...
(Date:2/4/2016)... 4, 2016  The Senior Care Pharmacy Coalition ... Committee Chairman Jason Chaffetz (R-UT) and ... hearing , "Developments in the Prescription Drug ... growing questions about abusive pharmacy benefit manager (PBM) ... and Ranking Member Elijah Cummings (D-MD) are diligent, ...
Breaking Medicine Technology: